Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer
Tóm tắt
The detection of serum tumor marker becomes a common method for screening tumors. However, this method has not been widely used for routine gastric cancer screening. In this study we aimed to determine whether the combined use of tumor markers may increase the sensitivity for the diagnosis of gastric cancer.
Serum AFP, CEA, CA125 and CA19-9 levels were measured in 149 patients with gastric cancer, 111 patients with benign gastric diseases and 124 healthy people, who visited the First Affiliated Hospital of Nanchang University from May 2011 to May 2012. Statistical analysis including receiver operating characteristic (ROC) curve, the area under the curve (AUC), and logistic regression analysis was performed to evaluate the diagnostic value of these markers on gastric cancer.
Serum levels of CEA, CA125, and CA19-9 in gastric cancer group were higher than that in the benign gastric disease group and the healthy control group (P <0.005). The sensitivity of AFP, CEA, CA125 and CA19-9 in the diagnosis of gastric cancer was 4.7-20.8% individually, and increased to 40.3% in combination. By using optimal cut-off value, the sensitivity of CEA, CA125, and CA19-9 for the diagnosis of gastric cancer was improved. Especially, the sensitivity of CEA increased to 58.4% and the sensitivity of combined use of four markers increased to 69.1%. The age and gender had no effects on the diagnostic value of these markers.
The determination and application of optimal cut-off values based on ROC curve and logistic regression analysis could improve the diagnosis of gastric cancer based on common tumor markers.
Từ khóa
Tài liệu tham khảo
Jackson C, Cunningham D, Oliveira J: Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009, 20 (Suppl 4): 34-36.
Haglund C, Kuusela P, Roberts P, Jalanko H: Tumour marker CA 125 in patients with digestive tract malignancies. Scand J Clin Lab Invest. 1991, 51 (3): 265-270. 10.3109/00365519109091613.
Ychou M, Duffour J, Kramar A: Clinical significance and prognostic Value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers. 2000, 16 (3–4): 105-110.
Li Y, Yang Y, Lu M: Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer. Hepatogastroenterology. 2011, 58 (112): 2166-2170.
Bornschein J, Selgrad M, Wex T, Kuester D, Malfertheiner P: Serological assessment of gastric mucosal atrophy in gastric cancer. BMC Gastroenterol. 2012, 12: 10-10.1186/1471-230X-12-10.
Zur B, Holdenrieder S, Walgenbach-Brünagel G, Albers E, Stoffel-Wagner B: Method comparison for determination of the tumor markers AFP, CEA, PSA and free PSA between Immulite 2000 XPI and Dimension Vista 1500. Clin Lab. 2012, 58 (1–2): 97-105.
Cui W, Lu X, Zheng S, Ma Y, Liu X, Zhang W: The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor. Clin Lab. 2012, 58 (5–6): 419-426.
Lai IR, Lee WJ, Huang MT: Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence. Hepatogastroenterol. 2002, 49: 1157-1160.
Chen XZ, Zhang WK, Kun Y: Correlation between serum CA724 and gastric cancer: multiple analyses based on Chinese population. Mol Biol Rep. 2012, 39: 9031-9039. 10.1007/s11033-012-1774-x.
Duraker N, Celik AN: The prognostic significance of preoperative serum CA 19–9 in patients with resectable gastric carcinoma: comparison with CEA. J Surg Oncol. 2001, 76 (4): 266-271. 10.1002/jso.1044.
Fan B, Xiong B: Investigation of serum tumor markers in the diagnosis of gastric cancer. Hepatogastroenterology. 2011, 58 (105): 239-245.
Mihmanli M, Dilege E, Demir U: The use of tumor markers as predictors of prognosis in gastric cancer. Hepatogastroenterology. 2004, 51 (59): 1544-1547.
Wobbes T, Thomas CM, Segers MF: Evaluation of seven tumor markers (CA 50, CA 19–9, CA 19–9 TruQuant, CA 72–4, CA 195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma. Cancer. 1992, 69 (8): 2036-2041. 10.1002/1097-0142(19920415)69:8<2036::AID-CNCR2820690805>3.0.CO;2-M.